Stockscreener 앱 받기
2.62
3.32%
-0.09
시간 외 거래:
2.65
0.03
+1.15%
전일 마감가:
$2.71
열려 있는:
$2.725
하루 거래량:
7.36M
Relative Volume:
2.50
시가총액:
$386.50M
수익:
$4.21M
순이익/손실:
$-97.67M
주가수익비율:
-2.8172
EPS:
-0.93
순현금흐름:
$-70.76M
1주 성능:
-6.09%
1개월 성능:
-3.68%
6개월 성능:
-5.42%
1년 성능:
-14.10%
1일 변동 폭
$2.61
$2.748
1주일 범위
$2.61
$2.86
52주 변동 폭
$2.01
$6.33
Absci Corp Stock (ABSI) Company Profile
명칭
Absci Corp
전화
(360) 949-1041
주소
18105 SE MILL PLAIN BLVD, VANCOUVER
ABSI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABSI
Absci Corp
|
2.62 | 386.50M | 4.21M | -97.67M | -70.76M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.30 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
521.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.83 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.14 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
241.20 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Absci Corp Stock (ABSI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-22 | 개시 | Needham | Buy |
| 2024-10-02 | 개시 | Guggenheim | Buy |
| 2024-07-03 | 개시 | Morgan Stanley | Overweight |
| 2024-03-14 | 개시 | Scotiabank | Sector Outperform |
| 2023-12-05 | 개시 | KeyBanc Capital Markets | Overweight |
| 2023-05-04 | 개시 | H.C. Wainwright | Buy |
| 2022-08-12 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2022-07-18 | 개시 | Truist | Buy |
| 2022-03-02 | 재개 | Cowen | Market Perform |
| 2022-02-01 | 개시 | Berenberg | Buy |
| 2021-11-10 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2021-10-15 | 재개 | Cowen | Market Perform |
| 2021-08-16 | 개시 | BofA Securities | Neutral |
| 2021-08-16 | 개시 | Cowen | Market Perform |
| 2021-08-16 | 개시 | Credit Suisse | Outperform |
| 2021-08-16 | 개시 | Stifel | Hold |
모두보기
Absci Corp 주식(ABSI)의 최신 뉴스
Millennium Management LLC Sells 1,149,603 Shares of Absci Co. (NASDAQ:ABSI) - MarketBeat
Absci Co. (NASDAQ:ABSI) Given Average Rating of "Buy" by Brokerages - MarketBeat
Transcript : Absci Corporation Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 08 - marketscreener.com
Two Sigma Investments LP Raises Stock Position in Absci Co. (NASDAQ:ABSI) - MarketBeat
Deutsche Bank AG Purchases 28,073 Shares of Absci Co. (NASDAQ:ABSI) - Defense World
Absci (NASDAQ:ABSI) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Top 5 AI & Digital Biotech Companies (June 2025) - Securities.io
Absci (NASDAQ:ABSI) Stock Rating Lowered by Wall Street Zen - Defense World
AbSci Corp (ABSI) Sees Borrow Rate Increase | ABSI Stock News - GuruFocus
Woodline Partners LP Decreases Position in Absci Co. (NASDAQ:ABSI) - MarketBeat
Northern Trust Corp Has $1.72 Million Stock Holdings in Absci Co. (NASDAQ:ABSI) - Defense World
Brokerages Set Absci Co. (NASDAQ:ABSI) Price Target at $8.40 - MarketBeat
Wall Street Zen Upgrades Absci (NASDAQ:ABSI) to Hold - Defense World
Ameriprise Financial Inc. Sells 23,668 Shares of Absci Co. (NASDAQ:ABSI) - Defense World
AbSci Corp (ABSI): Key Indicator Shows Noticeable Increase | ABSI Stock News - GuruFocus
Catherine Wood's Strategic Acquisition of Absci Corp Shares - GuruFocus
Schonfeld Strategic Advisors LLC Has $144,000 Stake in Absci Co. (NASDAQ:ABSI) - MarketBeat
Absci to Participate in Upcoming Investor Conferences - GlobeNewswire
Absci Sets Stage for Major AI Breakthroughs at Goldman Sachs and Jefferies Healthcare Conferences - Stock Titan
Needham & Company LLC Reiterates Buy Rating for Absci (NASDAQ:ABSI) - MarketBeat
Price T Rowe Associates Inc. MD Increases Holdings in Absci Co. (NASDAQ:ABSI) - Defense World
Absci Co. (NASDAQ:ABSI) Shares Sold by Stifel Financial Corp - Defense World
Needham & Company LLC Reaffirms “Buy” Rating for Absci (NASDAQ:ABSI) - Defense World
Absci Corp’s Earnings Call: A Promising Outlook - TipRanks
Absci Corporation (NASDAQ:ABSI) Q1 2025 Earnings Call Transcript - Insider Monkey
Absci First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Dimensional Fund Advisors LP Acquires 241,779 Shares of Absci Co. (NASDAQ:ABSI) - Defense World
ABSI: Needham Reiterates Buy Rating and $9 Price Target | ABSI Stock News - GuruFocus
Absci (ABSI) Initiates Phase 1 Study of AI-Designed Antibody ABS-101 | ABSI Stock News - GuruFocus
Absci (ABSI) Launches First Human Trial for ABS-101 - GuruFocus
ABSI: Needham Reiterates Buy Rating and $9 Price Target | ABSI S - GuruFocus
Assessing Absci: Insights From 6 Financial Analysts - Benzinga
Why Everus Construction Group Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket - Benzinga
Absci Corporation Advances Clinical Programs with Strong Q1 Results - TipRanks
Fred Alger Management LLC Reduces Position in Absci Co. (NASDAQ:ABSI) - MarketBeat
Absci Corp Q1 2025 Earnings: EPS Beats Estimates at -$0.21, Reve - GuruFocus
Absci earnings beat by $0.01, revenue fell short of estimates - Investing.com
Earnings call transcript: Absci Q1 2025 sees stock surge post-earnings By Investing.com - Investing.com Nigeria
AbSci (ABSI) Anticipates Significant Post-Earnings Movement | AB - GuruFocus
Earnings call transcript: Absci Q1 2025 sees stock surge post-earnings - Investing.com
Absci Q1 2025 Earnings Call Transcript - MarketBeat
Absci Corporation (ABSI) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Absci Corp reports results for the quarter ended March 31Earnings Summary - TradingView
ABSI Surprises with Q1 Revenue Beat and Expands Clinical Initiat - GuruFocus
ABSI Surprises with Q1 Revenue Beat and Expands Clinical Initiatives | ABSI Stock News - GuruFocus
Absci reports first participants dosed in Phase 1 ABS-101 trial - TipRanks
Absci Reports Business Updates and First Quarter 2025 Financial and Operating Results - GlobeNewswire
Absci Announces First Participants Dosed In Phase 1 Clinical Trial Of Abs-101, A Potential Best-In-Class Anti-TL1a Antibody For The Treatment Of Inflammatory Bowel Disease - marketscreener.com
Absci Announces First Participants Dosed in Phase 1 Clinical Trial of ABS-101, a Potential Best-In-Class anti-TL1A Antibody for the Treatment of Inflammatory Bowel Disease - GlobeNewswire
Breakthrough: First-Ever AI-Designed IBD Treatment Begins Human Trials with Quarterly Dosing Potential - Stock Titan
What To Expect From Absci Corp (ABSI) Q1 2025 Earnings - GuruFocus
Absci Corp (ABSI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.11%
1.70%
자본화:
|
볼륨(24시간):